Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
DYNABAC (dirithromycin) is an oral macrolide antibiotic approved in 1995 for treating bacterial infections. It is a semi-synthetic macrolide that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The delayed-release tablet formulation is designed to improve tolerability and compliance in patients with respiratory and skin infections.
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling smaller commercial teams focused on maintenance rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Semi-replicate Crossover Bioequivalence Study of Dirithromycin of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions
Semi-replicate Crossover Bioequivalence Study of Dirithromycin in Healthy Subjects Under Fed Conditions
Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting Condition
Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fed Condition
Worked on DYNABAC at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on DYNABAC offers limited career growth due to approaching LOE and mature lifecycle stage, with zero currently linked job openings. This role is best suited for professionals seeking stable, maintenance-focused experience in antibiotic portfolio management rather than high-growth career trajectories.